Operating Leverage Inflection
Expected: CurrentHIGH confidence
What: CDMO Margin Expansion: 338 bps QoQ
“The quarter also saw benefit of operating leverage playing out in the CDMO business, with improved capacity utilization.”
Akums Drugs & Pharmaceuticals Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +26.0%Strong6w Streak
In , Akums Drugs & Pharmaceuticals Ltd (Pharma - Formulators) is outperforming Nifty 500 with +26.0% relative strength. Fundamentals: Strong. On a 6-week streak.
Akums Drugs & Pharmaceuticals Ltd Key Facts
- PE Ratio
- 27.0x
- Market Cap
- ₹8,768 Cr
- PAT Growth YoY
- +3%
- Revenue Growth YoY
- +15%
- OPM
- 13.0%
- RS vs Nifty 500
- +26.0%
Strong Opportunity
What's Happening
💎PE falling while earnings hold — value emerging
🌐FII stake decreased 5.1% this quarter
🏛️DII accumulation — stake up 1.7%
💰Trading 98% below estimated fair value — significant discount
Earnings Acceleration Triggers
1. Operating Leverage Inflection
CurrentHIGH
2. Order Book Or Contract Wins
FY27HIGH
3. Geographical Expansion
CY2026MEDIUM
Key Risks
1. API prices, particularly Cephalosporins, remain under pressure with a 30% price
MEDIUM2. One-time impact of INR 18
LOW3. Stricter enforcement of Schedule M and government monitoring of cough syrups
LOWSector-Specific Signals
CDMO RevenueINR 916 Cr+16.3%
Overall Capacity Utilization47%
Estimated Peak Capacity55-60%
API Segment EBITDA LossINR 7 CrImproved
Key Numbers
PAT Growth YoY
+3%
Stable
Revenue YoY
+15%
Stable
Operating Margin
13.0%
+100 bps YoY
PE Ratio
27.0
Current Price
₹557
Fundamental Score
63/100
Strong
3Y PAT CAGR
+80%
Market Cap
8.8K Cr
Valuation
Significantly Undervalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
Why Are Akums Drugs & Pharmaceuticals Ltd's Earnings Accelerating?
Based on Q3 FY26 earnings • Updated Apr 18, 2026
Order Book Or Contract Wins
Expected: FY27HIGH confidence
What: EU CDMO Contract Value: EUR 35M/year
Impact: INR 300+ Cr revenue
“The annual run rate for the orders will be in the tune of EUR 35 million, and the contract is till December of 2032.”
Geographical Expansion
Expected: CY2026MEDIUM confidence
What: Zambia JV Revenue: $25M in 2026
Impact: INR 200 Cr revenue
“In 2026, we'll start seeing an additional INR2 00-odd crores from the Zambian supplies from India.”
Regulatory Approval Or License Win
Expected: January 2026MEDIUM confidence
What: EU GMP Accreditation: Plant 2 Approved
“Following the receipt of EU GMP accreditation for our oral liquids facility Plant number 2 and are on track to start supplies in FY '28.”
Market Share Gains
Expected: CurrentMEDIUM confidence
What: Volume Growth vs Market: 16% vs 1.5%
“Market growth was about 1.5%, but your volume growth has been significantly higher, which means that you've probably gained a lot of market share.”
CDMO Volume Growth of 16%+
HIGH confidence
What: CDMO Volume Growth of 16%+
“CDMO registered a healthy top-line growth of more than 16%, driven by strong volumes.”
What Are the Key Risks for Akums Drugs & Pharmaceuticals Ltd?
Earnings deceleration risks from management commentary
API prices, particularly Cephalosporins, remain under pressure with a 30% price
MEDIUMTrigger: Global downward trend in API pricing affects the cost-plus CDMO model and the standalone API business.
Impact: PAT impact: INR 7 Cr EBITDA loss in API segment
Management view: Focusing on non-cepha products and higher-margin molecules; cost optimization in manufacturing.
Monitor: commodity
One-time impact of INR 18
LOWTrigger: Regulatory changes in labor provisioning required a catch-up adjustment.
Impact: PAT impact: INR 18.2 Cr (one-time)
Management view: Included as an exceptional item; future impact expected to be minimal (INR 2.27 Cr for 9M).
Monitor: labor
Stricter enforcement of Schedule M and government monitoring of cough syrups
LOWTrigger: Increased regulatory scrutiny on manufacturing quality standards in India.
Management view: Company views this as a tailwind for quality-conscious players like Akums.
Monitor: regulatory
What Is Akums Drugs & Pharmaceuticals Ltd's Management Saying?
Key quotes from recent conference calls
“I think H2 should largely be similar as H1 as an overall year, given obviously the current market dynamics... H2 should largely mimic the H1. [Previous H2 Performance guidance]”
“We have recently initiated our SAP S/4HANA transformation, which will enable improved efficiency, automation, and real-time analytics. [Initiative: SAP S/4HANA Transformation]”
“This will largely be EUR35 million annually for us... starting in April of 2027. This is a six-year commercial supply contract. [Initiative: European CDMO Contract]”
“API business was struggling because largely it was dependent on cephalosporins, which had extensive price erosion of over 30%. [Risk (commodity): MEDIUM]”
What Did Akums Drugs & Pharmaceuticals Ltd Report This Quarter?
Headline numbers from the latest earnings call
Revenue
INR 1,160 crores
YoY +14.8%QoQ +14%
Why: Growth was primarily driven by double-digit volume growth in the CDMO business and a recovery in international branded formulations.
Revenue growth accelerated significantly from the flat performance seen in Q2.
EBITDA
INR 147 crores
YoY +21%Margin 12.7%
Why: Profitability improved due to operating leverage in the CDMO segment and reduced losses in the API and trade generics divisions.
EBITDA margins expanded by 338 basis points sequentially as capacity utilization improved.
PAT
INR 68 crores
YoY +2.1%QoQ +58.5%
Why: PAT growth was aided by strong operating performance but partially offset by a one-time labor code impact of INR 18.2 crores.
Sequential PAT growth was substantial despite the exceptional labor-related charge.
Other Highlights
• CDMO revenue grew 16.3% YoY to INR 916 crores.
• International branded formulation revenue increased 18% YoY to INR 50 crores.
• Cash surplus stood at INR 1,573 crores as of December 31, 2025.
What Sector Metrics Matter for Akums Drugs & Pharmaceuticals Ltd?
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
CDMO Revenue
INR 916 Cr
YoY +16.3%QoQ +13.8%
Why: Driven by double-digit volume growth across existing client portfolios.
Overall Capacity Utilization
47%
QoQ +700 bps
Why: Increased order inflow and ramp-up of newer facilities.
Estimated Peak Capacity
55-60%
Why: Limited by extensive changeovers for 20,000+ SKUs and preventive maintenance.
API Segment EBITDA Loss
INR 7 Cr
YoY ImprovedQoQ Improved
Why: Losses curtailed from INR 14 Cr in Q2 due to cost reduction and portfolio rationalization.
International Branded Revenue
INR 50 Cr
YoY +18%QoQ +127%
Why: Demand recovery in key markets like Philippines, Uganda, and Nigeria after a seasonally weak H1.
CDMO Gross Margin
37.3%
YoY +70 bpsQoQ -30 bps
Why: Stabilizing despite API price volatility; Q2 was 37.6%.
Total SKUs Manufactured
20,000
Total Customers
1,500
European Dossier Pipeline
10+
Why: Strategic focus on out-licensing and self-marketing in regulated markets.
API Segment COGS
87%
YoY -300 bpsQoQ -400 bps
Why: Improved from 91% in Q2 due to better product mix and cost optimization.
What Is Akums Drugs & Pharmaceuticals Ltd's Management Guidance?
Forward-looking targets from management for FY26-FY28
OPM Guidance
13–19%
Capex Plan
₹125 Cr
Revenue Outlook
INR 200-odd crores from Zambia in 2026; EUR 35 million annually from EU CDMO
Margin Outlook
CDMO margins expected to remain in the teens; EU contract margins slightly better than 13%.
Capex Plan
INR 100-125 crores
Maintenance, modernization, and R&D
Volume
Double-digit volume growth expected to sustain in the near term.
Management Tone: BULLISH
Guidance Changes
LOWERED
Domestic Branded Growth: Mid to teen digits → At par with industry growth
How Fast Is Akums Drugs & Pharmaceuticals Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +15% | +4% | Stable |
| PAT (Net Profit) | +3% | +80% | Stable |
| OPM | 13.0% | +100 bps | Stable |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 18, 2026.
Other Top Pharma - Formulators Stocks Beating Nifty 500
Frequently Asked Questions: Akums Drugs & Pharmaceuticals Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were Akums Drugs & Pharmaceuticals Ltd's latest quarterly results?
Akums Drugs & Pharmaceuticals Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +3.0% (stable)
- Revenue Growth YoY: +14.9%
- Operating Margin: 13.0% (stable)
Is Akums Drugs & Pharmaceuticals Ltd's profit growing or declining?
Akums Drugs & Pharmaceuticals Ltd's profit is growing with an stable trend.
- PAT Growth YoY: +3.0% (latest quarter)
- PAT Growth QoQ: +58.1% (sequential)
- 3-Year PAT CAGR: +80.0%
- Trend: Stable — consistent growth pattern
What is Akums Drugs & Pharmaceuticals Ltd's revenue growth trend?
Akums Drugs & Pharmaceuticals Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +14.9%
- Revenue Growth QoQ: +13.9% (sequential)
- 3-Year Revenue CAGR: +3.9%
How is Akums Drugs & Pharmaceuticals Ltd's operating margin trending?
Akums Drugs & Pharmaceuticals Ltd's operating margin is stable.
- Current OPM: 13.0%
- OPM Change YoY: +1.0% basis points
- OPM Change QoQ: +4.0% basis points
What is Akums Drugs & Pharmaceuticals Ltd's 3-year profit and revenue CAGR?
Akums Drugs & Pharmaceuticals Ltd's long-term compounding rates
- 3-Year Profit CAGR: +80.0%
- 3-Year Revenue CAGR: +3.9%
Is Akums Drugs & Pharmaceuticals Ltd's growth accelerating or decelerating?
Akums Drugs & Pharmaceuticals Ltd's earnings growth is stable with improving on a sequential basis.
- YoY Acceleration: +38.8% bps
- Sequential Acceleration: +83.8% bps
What is Akums Drugs & Pharmaceuticals Ltd's trailing twelve month (TTM) performance?
Akums Drugs & Pharmaceuticals Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹326 Cr
- TTM PAT Growth: +100.0% YoY
- TTM Revenue: ₹4,000 Cr
- TTM Revenue Growth: +6.3% YoY
- TTM Operating Margin: 11.1%
Is Akums Drugs & Pharmaceuticals Ltd overvalued or undervalued?
Akums Drugs & Pharmaceuticals Ltd appears significantly undervalued based on our fair value analysis.
- Valuation Signal: Significantly Undervalued
- Current PE: 27.0x
- Price-to-Book: 2.8x
What is Akums Drugs & Pharmaceuticals Ltd's current PE ratio?
Akums Drugs & Pharmaceuticals Ltd's current PE ratio is 27.0x.
- Current PE: 27.0x
- Market Cap: 8.8K Cr
How does Akums Drugs & Pharmaceuticals Ltd's valuation compare to its history?
Akums Drugs & Pharmaceuticals Ltd's current PE is 27.0x.
- Current PE: 27.0x
- Valuation Assessment: Significantly Undervalued
What is Akums Drugs & Pharmaceuticals Ltd's price-to-book ratio?
Akums Drugs & Pharmaceuticals Ltd's price-to-book ratio is 2.8x.
- Price-to-Book (P/B): 2.8x
- Book Value per Share: ₹200
- Current Price: ₹557
Is Akums Drugs & Pharmaceuticals Ltd a fundamentally strong company?
Akums Drugs & Pharmaceuticals Ltd is rated Strong with a fundamental score of 63.14/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +14.9% (10% weight)
- PAT Growth YoY: +3.0% (10% weight)
- PAT Growth QoQ: +58.1% (10% weight)
- Margins stable (10% weight)
Is Akums Drugs & Pharmaceuticals Ltd debt free?
Akums Drugs & Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹88 Cr
What is Akums Drugs & Pharmaceuticals Ltd's return on equity (ROE) and ROCE?
Akums Drugs & Pharmaceuticals Ltd's return ratios over recent years
- FY2023: ROCE 22.0%
- FY2024: ROCE 2.0%
- FY2025: ROCE 16.0%
Is Akums Drugs & Pharmaceuticals Ltd's cash flow positive?
Akums Drugs & Pharmaceuticals Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹465 Cr
- Free Cash Flow (FCF): ₹-83 Cr
- CFO/PAT Ratio: 135% (strong cash conversion)
What is Akums Drugs & Pharmaceuticals Ltd's dividend yield?
Akums Drugs & Pharmaceuticals Ltd currently does not pay a significant dividend (yield 0.00%).
- Dividend Yield: 0.00%
- Current Price: ₹557
Who holds Akums Drugs & Pharmaceuticals Ltd shares — promoters, FII, DII?
Akums Drugs & Pharmaceuticals Ltd's shareholding pattern (Mar 2026)
- Promoters: 75.3%
- FII (Foreign): 1.4%
- DII (Domestic): 14.4%
- Public: 6.3%
Is promoter holding increasing or decreasing in Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 75.3% (Mar 2026)
- Previous Quarter: 75.3% (Dec 2025)
- Change: 0.00% (stable)
How long has Akums Drugs & Pharmaceuticals Ltd been outperforming Nifty 500?
Akums Drugs & Pharmaceuticals Ltd has been outperforming Nifty 500 for 6 consecutive weeks, indicating building momentum.
Is Akums Drugs & Pharmaceuticals Ltd a new momentum entry or an established outperformer?
Akums Drugs & Pharmaceuticals Ltd is an established outperformer with 6 weeks of consecutive Nifty 500 outperformance.
What are the growth catalysts for Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd has 6 key growth catalysts identified from recent earnings analysis
- Operating Leverage Inflection — Improved capacity utilization and ramp-up of newer facilities are driving margins.
- Order Book Or Contract Wins — Sole supplier contract for a global pharma major provides long-term revenue visibility.
- Geographical Expansion — Supplying the Zambian government's essential medicine needs through a 51% JV.
- Regulatory Approval Or License Win — Approval allows the commencement of regulatory filings for the European market.
What are the key risks in Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd has 3 key risks worth monitoring
- [MEDIUM] API prices, particularly Cephalosporins, remain under pressure with a 30% price — Global downward trend in API pricing affects the cost-plus CDMO model and the standalone API business.
- [LOW] One-time impact of INR 18 — Regulatory changes in labor provisioning required a catch-up adjustment.
- [LOW] Stricter enforcement of Schedule M and government monitoring of cough syrups — Increased regulatory scrutiny on manufacturing quality standards in India.
What did Akums Drugs & Pharmaceuticals Ltd's management say in the latest earnings call?
In Q3 FY26, Akums Drugs & Pharmaceuticals Ltd's management highlighted
- "I think H2 should largely be similar as H1 as an overall year, given obviously the current market dynamics... H2 should largely mimic the H1. [Previo..."
- "We have recently initiated our SAP S/4HANA transformation, which will enable improved efficiency, automation, and real-time analytics. [Initiative: S..."
- "This will largely be EUR35 million annually for us... starting in April of 2027. This is a six-year commercial supply contract. [Initiative: European..."
What is Akums Drugs & Pharmaceuticals Ltd's management guidance for growth?
Akums Drugs & Pharmaceuticals Ltd's management has provided the following forward guidance for FY26-FY28
- Revenue outlook: INR 200-odd crores from Zambia in 2026; EUR 35 million annually from EU CDMO
- OPM guidance: 13–19%
- Capex plan: ₹125 Cr for Maintenance, modernization, and R&D
- Management tone: bullish
- Milestone: [LOWERED] Domestic Branded Growth: Mid to teen digits → At par with industry growth
What sector-specific metrics matter most for Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd's most important sub-sector-specific KPIs from the latest concall
- CDMO Revenue: INR 916 Cr (YoY +16.3%) (QoQ +13.8%) — Driven by double-digit volume growth across existing client portfolios.
- Overall Capacity Utilization: 47% (QoQ +700 bps) — Increased order inflow and ramp-up of newer facilities.
- Estimated Peak Capacity: 55-60% — Limited by extensive changeovers for 20,000+ SKUs and preventive maintenance.
- API Segment EBITDA Loss: INR 7 Cr (YoY Improved) (QoQ Improved) — Losses curtailed from INR 14 Cr in Q2 due to cost reduction and portfolio rationalization.
- International Branded Revenue: INR 50 Cr (YoY +18%) (QoQ +127%) — Demand recovery in key markets like Philippines, Uganda, and Nigeria after a seasonally weak H1.
- CDMO Gross Margin: 37.3% (YoY +70 bps) (QoQ -30 bps) — Stabilizing despite API price volatility; Q2 was 37.6%.
Is Akums Drugs & Pharmaceuticals Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Akums Drugs & Pharmaceuticals Ltd may be worth studying
- Earnings growing at +3.0% YoY
- Valuation: appears significantly undervalued
- Cash flow is positive — CFO ₹465 Cr
What is the investment thesis for Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +14.9% YoY
- Appears significantly undervalued
- Growth catalyst: Operating Leverage Inflection
Risk Factors (Bear Case)
- Key risk: API prices, particularly Cephalosporins, remain under pressure with a 30% price
What is the future outlook for Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: stable
- Margin Trend: stable
- Valuation: Significantly Undervalued
- Key Catalyst: Operating Leverage Inflection
- Key Risk: API prices, particularly Cephalosporins, remain under pressure with a 30% price
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.